Through its partnerships with academic research institutions, health departments, and study sites across the globe, Tuberculosis Trials Consortium (TBTC), a part of the U.S. Centers for Disease Control (CDC)’s Division of TB Elimination (DTBE), plays a critical role in advancing research and development for tuberculosis. The TBTC creates opportunities for collaboration in robust clinical trials that reflect innovative approaches to tackle the TB pandemic. However, the TBTC has received flat funding from Congress for many years. The effects of inflation essentially make this a funding cut, compromising the institutional knowledge that researchers and health departments have cultivated together.

This publication explores the critical role the TBTC holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.